̽��ֱ�� of Cambridge - MRC Laboratory of Molecular Biology

̽��ֱ��Royal Society announces election of new Fellows 2021

cg605 — Thu, 06 May 2021 10:48:11 +0000

Over 60 outstanding scientists from all over the globe have joined the Royal Society as Fellows and Foreign Members. ̽��ֱ��distinguished group of scientists consists of 52 Fellows, 10 Foreign Members and one Honorary Fellow and were all selected for their exceptional contributions to science.

̽��ֱ��Royal Society is a self-governing Fellowship made up of the most eminent scientists, engineers and technologists from the UK and the Commonwealth. Its Foreign Members are drawn from the rest of the world.

̽��ֱ��Society’s fundamental purpose is to recognise, promote, and support excellence in science and to encourage the development and use of science for the benefit of humanity.

“ ̽��ֱ��global pandemic has demonstrated the continuing importance of scientific thinking and collaboration across borders,” said President of the Royal Society, Sir Adrian Smith.

“Each Fellow and Foreign Member bring their area of scientific expertise to the Royal Society and when combined, this expertise supports the use of science for the benefit of humanity.

“Our new Fellows and Foreign Members are all at the forefronts of their fields from molecular genetics and cancer research to tropical open ecosystems and radar technology. It is an absolute pleasure and honour to have them join us.”

̽��ֱ�� of Cambridge:

Professor Julie Ahringer FMedSci FRS

Director and a Senior Group Leader of the Gurdon Institute

Professor Ahringer has made wide-ranging contributions to molecular genetics through her work on the nematode C. elegans. She carried out the first systematic inactivation of all the genes in any animal, which pioneered genome-wide reverse genetic screening.

Her research has illuminated our understanding of the processes underlying cell polarity and gene expression. This includes showing that spindle positioning is controlled by heterotrimeric G protein signalling, discovering a connection between chromatin marking and mRNA splicing, and most recently revealing mechanisms and principles of genome organisation and gene expression regulation.

“I am honoured to be elected as a Fellow of the Royal Society,” said Ahringer. “Much of science today is done in teams, and this reflects the tremendous contributions of my past and present lab members.”

Professor Sadaf Farooqi FRCP FMedSci FRS

Wellcome Principal Research Fellow and Professor of Metabolism and Medicine, Wellcome-MRC Institute of Metabolic Science

Professor Farooqi is distinguished for her discoveries of fundamental mechanisms that control human energy homeostasis and their disruption in obesity. Farooqi discovered that the leptin-melanocortin system regulates appetite and weight in people and that genetic mutations affecting this pathway cause severe obesity. Findings by her team have directly led to diagnostic testing for genetic obesity syndromes world-wide and enabled life-saving treatment for some people with severe obesity.

Farooqi said: “As a clinician scientist, I am absolutely delighted to be elected to the Fellowship of the Royal Society. This prestigious honour recognises the work of many team members past and present, our network of collaborators across the world and the patients and their families who have contributed to our research.”

Professor Usha Goswami CBE FBA FRS

Professor of Cognitive Developmental Neuroscience, Department of Psychology, and Director of the Centre for Neuroscience in Education

Professor Goswami has pioneered the application of neuroscience to education. Her research investigates the sensory and neural basis of childhood disorders of language and literacy, which are heritable and found across languages. Goswami's research shows a shared sensory and neural basis in auditory rhythmic processing. ̽��ֱ��acoustic ‘landmarks’ for speech rhythm provide automatic triggers for aligning speech rhythms and brain rhythms, and Goswami has shown that this automatic process can be disrupted, thereby disrupting speech encoding for these children.

“It is a huge honour to be elected to the Royal Society and a wonderful acknowledgement of our research in the Centre for Neuroscience in Education,” said Goswami. “I have been interested in children's reading and language development since training as a primary school teacher, and we have used neuroscientific insights to understand the mechanisms underpinning developmental language disorders. It is fantastically rewarding for our work to be recognised in this way.”

Professor Rebecca Kilner FRS

Professor of Evolutionary Biology and Director of the ̽��ֱ�� Museum of Zoology

Professor Kilner researches the evolution of animal behaviour, and how this behaviour then affects the pace and scope of subsequent evolutionary change. Using experimental evolution, her current work investigates how quickly populations can adapt when environmental conditions change.

Kilner discovered novel ways in which social behaviour drives evolutionary change. She used elegant cross-fostering experiments in birds and insects to expose how family members exert selection on each other, and discovered hidden evolutionary conflicts between parents and their offspring, and among adults caring together for offspring.

Kilner said: “I’m astonished, honoured and delighted to be elected to the Fellowship of the Royal Society. This honour is shared with everyone I have ever worked with. Science is a team effort and I’ve been incredibly lucky to collaborate with brilliant colleagues throughout my career.”

Professor David Rowitch FMedSci FRS

Professor and Head of the Department of Paediatrics, Wellcome Trust Senior Investigator

Professor Rowitch’s basic and translational research on glial cells, comprising 90% of cells in the human brain, has been transformative. Rowitch’s established how embryonic central nervous patterning specifies myelinating oligodendrocytes through essential functions of Olig2, a study that helped initiate genetic methodologies in glial biology, and how astrocyte functional diversification is critical for support of neural circuits in the spinal cord. He has applied a developmental neuroscience perspective to better understand human neonatal brain development and white matter injury in premature infants, multiple sclerosis and leukodystrophy.

Rowitch said: “It is a great honour to be elected to the Fellowship of the Royal Society, joining many of my esteemed Cambridge, and other scientific, colleagues.”

Professor Richard Samworth FRS

Professor of Statistical Science and Director of the Statistical Laboratory

Professor Samworth has made fundamental contributions to the development of modern statistical methodology and theory. His research concerns the development of statistical methods and theory to address contemporary data challenges, often posed by the large volumes of data that are routinely collected in today's Big Data era.

“I was incredibly honoured when I found out I'd been elected a Fellow of the Royal Society,” said Samworth. “It's a real thrill to become a small part of such a respected institution.”

Professor Benjamin Simons FRS

Royal Society EP Abraham Professor, Department of Applied Mathematics and Theoretical Physics and Senior Group Leader of the Gurdon Institute

As a theorist, Professor Simons has contributed to a diverse range of fields, from quantum condensed matter physics to developmental and cancer biology. His research translates concepts and approaches from statistical physics to gain predictive insights in the collective dynamics of complex systems. In biology, his studies have revealed common mechanisms of stem cell regulation, and how these programmes become subverted during the early phase of tumour growth.

Simons said: “I am delighted to be elected to the Fellowship. I hope that my election may serve to emphasise the value of multidisciplinary research that stands at the interface between physics and the life sciences.”

Wellcome Sanger Institute:

Dr Peter Campbell FMedSci FRS, Head, Cancer, Ageing, and Somatic Mutations Programme, Wellcome Sanger Institute (and Wellcome-MRC Stem Cell Institute, ̽��ֱ�� of Cambridge).

MRC Laboratory of Molecular Biology:

Dr Christopher Tate FRS, MRC Investigator, MRC Laboratory of Molecular Biology

Dr Sjors Scheres FRS, Group Leader, Structural Studies Division, MRC Laboratory of Molecular Biology

British Antarctic Survey:

Professor Dame Jane Francis DCMG FRS, Director, British Antarctic Survey

Professor Richard Horne FRS, Head, Space Weather and Atmosphere, British Antarctic Survey

Cambridge scientists are among the new Fellows announced today by the Royal Society.

Our new Fellows and Foreign Members are all at the forefronts of their fields from molecular genetics and cancer research to tropical open ecosystems and radar technology.

Sir Adrian Smith, President of the Royal Society

̽��ֱ��text in this work is licensed under a Creative Commons Attribution 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Cambridge start-up raises £40 million in funding to develop new cancer treatments

Anonymous — Fri, 16 Jun 2017 04:00:00 +0000

Among the investors in the new funding round is Cambridge Innovation Capital, which invests in companies based on valuable intellectual property in the Cambridge Cluster, or with links to the ̽��ֱ�� of Cambridge. ̽��ֱ�� ̽��ֱ�� is the largest investor in Cambridge Innovation Capital (CIC), which was founded by Cambridge Enterprise, the ̽��ֱ��’s commercialisation arm, in 2013.

Bicycle Therapeutics is developing a new class of drugs called ‘Bicycles’, which are based on small protein chains, or peptides, which have been chemically constrained, and have a similar shape to a bicycle wheel. They have been designed to combine the best features of small molecule and antibody based drugs. ̽��ֱ��science behind the creation of Bicycles is based on work initiated at the MRC Laboratory of Molecular Biology by Professor Sir Greg Winter, a pioneer in monoclonal antibody development and the Master of Trinity College, working together with Professor Christian Heinis from the Ecole Polytechnique Fédérale de Lausanne.

‘Bicycles’ have a range properties which make them an excellent choice as a potential drug. They have the binding capacity and specificity of an antibody, but can penetrate tissue such as solid tumours easily because of their relatively small size. In addition, due to their small size and peptidic nature, they are cleared from the body via the kidneys, allowing them to be designed in such a way as to maximise their efficiency while minimising the chance of any side effects.

Bicycle Therapeutics’ most advanced potential product, known as BT1718, is the first example of its Bicycle Drug Conjugate® (BDC) technology, in which the Bicycle is targeted to bind specifically to malignant tumours and is harnessed to a chemical payload designed to destroy cancer cells once it reaches its target.

BT1718 targets a cell surface protein called Membrane Type 1 Matrix Metalloproteinase (MT1-MTP). MT1-MTP occurs in high concentration in many solid malignant tumours. Consequently BT1718 may have the capacity to become a treatment for a range of cancers which currently do not have good treatment options such as ‘triple negative’ breast cancer and non-small cell lung cancer. It is expected to enter clinical trials in 2017 in partnership with Cancer Research UK.

Bicycle Therapeutics is not the first start-up in which Professor Winter has been involved. Cambridge Antibody Therapeutics, the discoverers of rheumatoid arthritis drug Humira, and Domantis were both based on his work on therapeutic monoclonal antibodies. This work has enabled great improvements in the treatment of cancer and immune disorders and, as a result, many of the world’s blockbuster pharmaceutical drugs are based on the techniques he developed.

“ ̽��ֱ��pre-clinical studies to date show Bicycles have many of the attributes needed to be an effective medical treatment,” said Dr Michael Anstey, Investment Director at CIC. “ ̽��ֱ��next big step is to take this into humans and if they show the same characteristics this will be very exciting. Bicycle Therapeutics is an ambitious company, with a world-class team, that has all the ingredients for another Cambridge success story.”

“I am delighted that Bicycle Therapeutics has secured this new funding to enable the team to move multiple programmes into the clinic,” said Professor Winter. “Bicycles are different from both antibodies and small molecules, with some of the benefits of each, giving them the potential to deliver an exciting new class of therapeutics across different diseases.”

“This financing represents an important validation of our approach, while providing Bicycle Therapeutics with the resources to continue to turn our bicyclic peptide technology into important new treatment options for patients,” said Dr Kevin Lee, Bicycle Therapeutics’ CEO. “We are grateful for the strong support from our investors as we move BT1718 rapidly towards the clinic and continue to advance our other preclinical programmes, that have the potential to treat cancer and other debilitating diseases.”

Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.

Bicycle Therapeutics is an ambitious company, with a world-class team, that has all the ingredients for another Cambridge success story.

Michael Anstey

Bicycle Therapeutics

Bicyclic peptides

̽��ֱ��text in this work is licensed under a Creative Commons Attribution 4.0 International License. For image use please see separate credits above.

Yes